Loading...
XJPX
8086
Market cap1.37bUSD
Oct 09, Last price  
1,319.00JPY
1D
-0.86%
1Q
-14.71%
Jan 2017
3.21%
Name

Nipro Corp

Chart & performance

D1W1MN
XJPX:8086 chart
P/E
15.93
P/S
0.33
EPS
82.80
Div yield, %
2.25%
Shrs. gr., 5y
2.45%
Rev. gr., 5y
7.71%
Revenues
660.54b
+2.47%
184,362,000,000172,113,000,000175,944,000,000177,829,000,000195,942,000,000212,013,000,000241,020,000,000300,752,000,000325,084,000,000366,650,000,000359,699,000,000395,397,000,000426,399,000,000442,516,000,000455,559,000,000494,789,000,000545,199,000,000586,785,000,000644,586,000,000660,538,000,000
Net income
13.50b
+164.06%
8,555,000,0004,454,000,0004,532,000,0007,252,000,0002,455,000,0004,585,000,00010,231,000,0002,861,000,00012,470,000,00019,718,000,00011,346,000,00011,830,000,00012,136,000,000-12,281,000,00014,210,000,00013,455,000,0004,575,000,00011,109,000,0005,114,000,00013,504,000,000
CFO
54.66b
-20.16%
14,488,000,0009,675,000,00018,851,000,00026,240,000,00021,799,000,00015,486,000,00022,593,000,00021,552,000,00027,981,000,00029,934,000,00033,472,000,00041,046,000,00041,362,000,00037,246,000,00066,093,000,00068,214,000,00010,395,000,00072,936,000,00068,461,000,00054,657,000,000
Dividend
Mar 30, 202720 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.

Related entities

Subsidiaries (5)
NIPRO EUROPE GROUP COMPANIES
NIPRO PHARMAPACKAGING INDIA PRIVATE LIMITED
Nipro Digital Technologies Europe
NIPRO MEDICAL EUROPE
Nipro PharmaPackaging International

Key people

Noriyoshi Iwasaki
Executive Officer · since 2024
Toshiya Kai
Executive Officer, Director in Main Reliability Assurance Unit · since 2024
Naohisa Kawamura
Executive Officer, Director of Pharmaceutical Research Institute in Pharmaceutical Business Unit, Director of Research Planning, Director of Quality Assurance Unit · since 2024
Akira Kondo
Executive Officer, Chief Director of Production Business Unit in Main Pharma Packaging Unit · since 2024
Yasuhiko Morita
Executive Officer, Ch. Dir. of Main MEP Unit in Main Development and Technology Supervision Unit, Dir. of Clinical Development, Manager of Nipro Life Science Site Center, Manager of CR Center · since 2022
Naoki Okamoto
Executive Officer, Director of Domestic Business Unit in Main Product Strategy Unit, Director of Business Strategy Office · since 2024
Tomohiro Otsuka
Executive Officer, Chief Director of Domestic Business Unit in Main Medical Sales Unit · since 2024
Kaname Sadahiro
Executive Officer, Ch Dir of International Product Develop & Tech Sales in International Business , Dir in Blood Purification Product Develop/Tech Sales Unit, Dir in New Product DevelopTech Sales · since 2024
Akira Shimizu
Executive Officer, Chief Director of Sales in International Business Unit · since 2023
Hiroshi Sudo
Executive Officer, Chief Director of Product Planning in Planning & Development Technology Business Unit · since 2022
Yasunobu Tamaki
Executive Officer, Manager of Audit Office · since 2025
Zennin Yamagata
Executive Officer, Senior Chief Director of Manufacturing in Regenerative Medicine Unit, Director of Administration in Main Business Administration Unit · since 2024
Yoshiharu Yonemori
Executive Officer, Ch Dir of Domestic Medical Device Production, Ch Dir of International Medical Device Production, Man of Odate Factory · since 2024
Hiroshi Yoshida
Executive Officer, Director of 3rd Research and Development in General Research Institute, Manager of Enzyme Center in Planning & Development Technology Unit, Manager of LFR Business Office · since 2022
Taku Nikaido
Director of Domestic Business, Director · since 2025
Toyoshi Yoshida
Chief Director of Credibility Assurance, Director · since 2019
Kyoetsu Kobayashi
Managing Director, Chief Director of Stable Production and Crisis Administration · since 2023
Kimihito Minoura
Managing Director, Chief Director of Business Promotion, Chief Director of Business Administration, Chief Director of New Business Development, Director of Regenerative Medicine Business, · since 2024
Hideyuki Nishisako
Director of Pharma Packaging Business, Director · since 2025
Yasushi Ohyama
Senior Managing Director, Director of Vascular Business, President of Subsidiary · since 2024
IPO date
Feb 01, 1987
Employees
38,770
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
千里丘新町3番26号
⼤阪府 摂津市 566-8510
JP
Address
3-26, Senriokashinmachi
Settsu Osaka 566-8510
JP
Other language
NIPRO CORPORATION

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT